SAINT I (Stroke - Acute Ischemic - NXY Treatment) a double blind, randomized, placebo controlled, parallel group, multicenter, phase IIb/III study to assess the efficacy and safety of intravenous NXY-059 [disufenton, Cerovive(Rm); AstraZeneca] in acute ischemic stroke

Trial Profile

SAINT I (Stroke - Acute Ischemic - NXY Treatment) a double blind, randomized, placebo controlled, parallel group, multicenter, phase IIb/III study to assess the efficacy and safety of intravenous NXY-059 [disufenton, Cerovive(Rm); AstraZeneca] in acute ischemic stroke

Completed
Phase of Trial: Phase II/III

Latest Information Update: 24 Mar 2009

At a glance

  • Drugs Disufenton (Primary)
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms SAINT-I
  • Most Recent Events

    • 06 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top